Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercial

Strategy Explore this Topic

Set Alert for Strategy

Coherus Completes $50m Share Offer To Novel Partner Junshi Biosciences

Coherus BioSciences has sold a little under 2.5 million shares to partner Junshi Biosciences, giving the firm additional capital following a large debt financing last year.

Deals Financing

Alvogen’s Lotus Bags $50m Investment To Boost Access In Asia

Lotus Pharmaceuticals aims to build a stronghold in Thailand and beyond, after the Alvogen subsidiary announced a partnership with a subsidiary of Thai state-owned conglomerate PTT, which includes a $50m capital injection.

Deals Strategy

Aurobindo’s Latest Launches Include Truvada And Atripla Rivals

Aurobindo has announced the launch of generic versions of Truvada, Atripla, Minocin and Gleevec in the US. As its generics business grows in the US, Europe, Canada and the rest of the world markets, Aurobindo plans to establish itself in China. The Indian pharma company has also announced its plan to commission new facilities to serve the external market. 

Approvals Launches
See All

Deals Explore this Topic

Set Alert for Deals

Coherus Completes $50m Share Offer To Novel Partner Junshi Biosciences

Coherus BioSciences has sold a little under 2.5 million shares to partner Junshi Biosciences, giving the firm additional capital following a large debt financing last year.

Deals Financing

Alvogen’s Lotus Bags $50m Investment To Boost Access In Asia

Lotus Pharmaceuticals aims to build a stronghold in Thailand and beyond, after the Alvogen subsidiary announced a partnership with a subsidiary of Thai state-owned conglomerate PTT, which includes a $50m capital injection.

Deals Strategy

PlantForm Strikes Deal For Brazilian Pembrolizumab

Canada’s PlantForm has struck a deal with Brazil’s Bio-Manguinhos/Fiocruz to develop a biosimilar pembrolizumab rival to Merck’s Keytruda for the Brazilian market and potentially beyond.

Deals Biosimilars
See All

Manufacturing Explore this Topic

Set Alert for Manufacturing

Aurobindo’s Latest Launches Include Truvada And Atripla Rivals

Aurobindo has announced the launch of generic versions of Truvada, Atripla, Minocin and Gleevec in the US. As its generics business grows in the US, Europe, Canada and the rest of the world markets, Aurobindo plans to establish itself in China. The Indian pharma company has also announced its plan to commission new facilities to serve the external market. 

Approvals Launches

FDA Guides On Virtual Inspections During COVID-19

Details of how the FDA plans to conduct remote evaluations of manufacturing facilities during the COVID-19 pandemic have been set out in guidance published by the US agency.

Guidance Documents Regulation

Nichi-Iko Resumes Production After Suspension

Nichi Iko says it has restarted production at its Namerikawa manufacturing plant after the Japanese firm was forced to suspend operations due to alleged GMP violations.

Manufacturing Legal Issues
See All

Sales & Earnings Explore this Topic

Set Alert for Sales & Earnings

Aurobindo’s Latest Launches Include Truvada And Atripla Rivals

Aurobindo has announced the launch of generic versions of Truvada, Atripla, Minocin and Gleevec in the US. As its generics business grows in the US, Europe, Canada and the rest of the world markets, Aurobindo plans to establish itself in China. The Indian pharma company has also announced its plan to commission new facilities to serve the external market. 

Approvals Launches

Henlius Capitalizes On Biosimilar Launches

Henlius has announced plans to expand its global footprint and bolster its manufacturing capacity after seeing its sales shoot up in 2020 based on three new launches.

China BioPharmaceutical

Amphastar Pipeline Targets $10.5bn Market With Seven Generics

Amphastar announces that it has seven generic and three biosimilar products in development in order to target bigger markets. The company revealed that its insulin program is also developing towards interchangeable status. 

Approvals Generic Drugs
See All

People Explore this Topic

Set Alert for People

New Fresenius Kabi Chief Sen Adds Sandoz’ Pawlu

As Michael Sen takes the reins as CEO of Fresenius Kabi, Christian Pawlu has been recruited from Sandoz to head up the firm’s generics and complex formulations unit.

Appointments Leadership

Neuraxpharm Expands Into The Nordics With New Leader From Viatris

In line with its plan to expand into the Nordics, CNS specialist Neuraxpharm has established a new business unit in Stockholm and has recruited Viatris’ Magnus Wassén to lead it as general manager. The company is expecting Neuraxpharm Sweden to provide an immediate sales platform for Buccolam. 

Europe Appointments

Belgium’s Medaxes Appoints New Board

Belgian industry association Medaxes has appointed a new board at the same time as revealing plans for a biosimilars awareness day in April, following in the footsteps of a recent initiative focused on generics.

Belgium Appointments
See All
UsernamePublicRestriction

Register